Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 24, 2022 17:56 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022 11:43 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of...
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
April 05, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana...
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
March 25, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022. NEW YORK, March 25, 2022 (GLOBE...
Tiziana Announces Availability of March 14 KOL Event Replay
March 15, 2022 14:15 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
March 11, 2022 07:17 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
March 10, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapyData show sustained inhibition of...
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
March 01, 2022 09:05 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today...
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
February 10, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
February 04, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd...